Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Marina Martello
Observed names:
M Martello,
M. Martello,
Martello, Marina <1983>
Institutions:
Istituto di Ematologia di Bologna,
University of Bologna
Observed institutions:
University Hospital Heidelberg,
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
Istituto di Ematologia di Bologna,
University of Bologna
ORCID:
0000-0001-8196-8707
Observed ORCID:
0000-0001-8196-8707
OpenAlex ID:
A5065076609
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma
2015
·
Elena Zamagni
, Cristina Nanni
, et al.
·
Clinical Cancer Research
·
182
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma
2020
·
Bachisio Ziccheddu
, Giulia Biancon
, et al.
·
Blood Advances
·
76
Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma
2014
·
Enrica Borsi
, Carolina Terragna
, et al.
·
Translational research
·
62
Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?
2020
·
Niccolo Bolli
, Elisa Genuardi
, et al.
·
Frontiers in Oncology
·
59
PDF
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
2019
·
Alessandra Romano
, Giuseppe Alberto Palumbo
, et al.
·
Frontiers in Oncology
·
59
PDF
Bortezomib‐ and thalidomide‐induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study
2014
·
Paola Tacchetti
, Carolina Terragna
, et al.
·
American Journal of Hematology
·
57
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma
2014
·
Enrica Borsi
, Giulia Perrone
, et al.
·
Oncotarget
·
57
PDF
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
2022
·
M. Martello
, A. Poletti
, et al.
·
Blood Cancer Journal
·
47
PDF
A real‐world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma
2020
·
Serena Rocchi
, Paola Tacchetti
, et al.
·
Hematological Oncology
·
37
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
2015
·
Carolina Terragna
, Daniel Remondini
, et al.
·
Oncotarget
·
31
PDF
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment
2014
·
Enrica Borsi
, Giulia Perrone
, et al.
·
Experimental Cell Research
·
31
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis
2024
·
Marina Martello
, Vincenza Solli
, et al.
·
Blood Cancer Journal
·
24
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens
2016
·
Paola Tacchetti
, Michele Cavo
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
20
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases
2022
·
Ilaria Vigliotta
, Silvia Armuzzi
, et al.
·
Frontiers in Oncology
·
14
PDF
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138−CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis
2016
·
M Martello
, D Remondini
, et al.
·
Leukemia
·
14
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features
2024
·
Carolina Terragna
, Andrea Poletti
, et al.
·
Nature Communications
·
13
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia
2021
·
Alessandro Broccoli
, Carolina Terragna
, et al.
·
Hematological Oncology
·
13
PDF
Molecular Remission After Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Consolidation Therapy Following Double Autologous Transplantation for Multiple Myeloma: Results of a Qualitative and Quantitative Analysis
2010
·
Carolina Terragna
, Elena Zamagni
, et al.
·
Blood
·
13
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients
2024
·
Enrica Borsi
, Ilaria Vigliotta
, et al.
·
Cells
·
11
PDF
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma
2023
·
Katia Mancuso
, Elena Zamagni
, et al.
·
Frontiers in Oncology
·
11
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation
2013
·
Carolina Terragna
, Matteo Renzulli
, et al.
·
Annals of Hematology
·
11
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients
2024
·
Ilaria Vigliotta
, Vincenza Solli
, et al.
·
Cancers
·
9
PDF
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients
2023
·
Enrica Borsi
, Gaia Mazzocchetti
, et al.
·
Clinical and Experimental Medicine
·
7
PDF
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma
2015
·
L. Pantani
, A. Brioli
, et al.
·
Expert Review of Hematology
·
7
PDF
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma
2025
·
Andrea Poletti
, Barbara Taurisano
, et al.
·
Haematologica
·
6
Show more works
View as search
Works count:
108
Citation count:
929
H-index:
14
I10-index:
21
Year
Topic
Type